Iżrael - Ebrajk - Ministry of Health

neopharm ltd, israel - lonafarnib - קפסולות ג'לטין קשיחות - lonafarnib 50 mg - lonafarnib

Iżrael - Ebrajk - Ministry of Health

neopharm ltd, israel - lonafarnib - קפסולות ג'לטין קשיחות - lonafarnib 75 mg - lonafarnib

Iżrael - Ebrajk - Ministry of Health

j-c health care ltd - domperidone - טבליה - domperidone 10 mg - domperidone - domperidone - dyspeptic complaints associated with slow gastric evacuation or esophageal reflux such as epigastric sense of fullness, feeling of abdominal distention, upper abdominal pain, eructation, flatulence, nausea and vomiting, heartburn, with or without regurgitation of gastric contents into the mouth. nausea, vomiting and hiccups of various origin such as functional, organic, infectious, dietetic, following radiotherapy or as a result of drug therapy, in particular when induced by dopamine agonists like in parkinson's disease.

Iżrael - Ebrajk - Ministry of Health

teva israel ltd - benzylpenicillin sodium - אבקה להכנת תמיסה לזריקה - benzylpenicillin sodium 5 miu/vial - benzylpenicillin - benzylpenicillin - infections due to penicillin sensitive organisms.

Iżrael - Ebrajk - Ministry of Health

teva israel ltd - benzylpenicillin sodium - אבקה להכנת תמיסה לזריקה - benzylpenicillin sodium 10 mu/vial - benzylpenicillin - benzylpenicillin - infections due to penicillin - sensitive microorganisms.

Iżrael - Ebrajk - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Iżrael - Ebrajk - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Iżrael - Ebrajk - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 2 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Iżrael - Ebrajk - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.